Aclaris Therapeutics Competitors and Similar CompaniesClear all

Aclaris Therapeutics's competitors and similar companies include UCB, CSL Behring, Cadila Pharmaceuticals and Cipla.

	Aclaris Therapeutics Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	CSL Behring CSL Behring is a provider of life-saving medicines.	Cadila Pharmaceuticals Cadila Pharmaceuticals is a company that develops and manufactures medicines for patients.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 2012	Founding Date 1928	Founding Date 1904	Founding Date 1951	Founding Date 1935
Type	Type Public	Type Public	Type Subsidiary	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Chesterbrook, US HQ St. Louis, US	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more	Locations Bavla, IN HQ Akaki, ET Dholka, IN Chiyoda City, JP Nairobi, KE Moskva, RU Ascot, GB see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 7556% decrease	Employees 9,052	Employees 7,5692% decrease	Employees 8,5201% increase	Employees 27,764
Valuation ($)	Valuation ($) 122 m	Valuation ($) 34.3 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $7.8m (FY, 2025)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) $7.9b (FY, 2020)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods $2.1m (FY, 2025)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹97.2b (FY, 2026)
Gross profit	Gross profit $5.7m (FY, 2025)	Gross profit €7.2b (FY, 2025)	Gross profit $4.5b (FY, 2020)	Gross profit N/A	Gross profit ₹184.4b (FY, 2026)
Net income	Net income ($64.9m) (FY, 2025)	Net income €1.6b (FY, 2025)	Net income N/A	Net income N/A	Net income ₹38.7b (FY, 2026)
Operating ⚠
Countries	Countries N/A	Countries 35 (FY, 2019)	Countries 100 (Dec, 2020)	Countries N/A	Countries N/A